Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

Blood Cancer J. 2021 Mar 12;11(3):55. doi: 10.1038/s41408-021-00438-y.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Dexamethasone / therapeutic use*
  • Humans
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy*
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / drug therapy*
  • Prognosis
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Thalidomide
  • Dexamethasone
  • pomalidomide
  • isatuximab